Contraception
Volume 81, Issue 2 , Pages 102-106 , February 2010

Effect of a continuous regimen of contraceptive combination of ethinylestradiol and drospirenone on lipid, carbohydrate and coagulation profiles

  • Rogério Bonassi Machado

      Affiliations

    • Department of Obstetrics and Gynecology, Jundiaí School of Medicine, 13202-550 Jundiaí, São Paulo, Brazil
    • Corresponding Author InformationCorresponding author. Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina de Jundiaí., R. Francisco Telles 250, 13202-550 Jundiaí, São Paulo, Brazil. Tel.: +55 11 4521 6466; fax: +55 11 4521 6040.
    • ,
  • Nilson Roberto de Melo

      Affiliations

    • Department of Obstetrics and Gynecology, School of Medicine, University of São Paulo, 05403-900 São Paulo, Brazil
    • ,
  • Hugo Maia Jr.

      Affiliations

    • Centro de Pesquisa e Assistência em Reprodução Humana (CEPARH), 44015-340 Salvador, Bahia, Brazil
    • ,
  • Achilles Machado Cruz

      Affiliations

    • Department of Obstetrics and Gynecology, Jundiaí School of Medicine, 13202-550 Jundiaí, São Paulo, Brazil

Received 9 June 2009 ,Accepted 25 August 2009.

References 

  1. Fu H, Darroch JE, Haas T, Ranjit N. Contraceptive failure rates: new estimates from the 1995 National Survey of Family Growth. Fam Plann Perspect. 1999;31:56–63
  2. Chandra A, Martinez GM, Mosher WD, Abma JC, Jones J. Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth. Vital Health Stat. 2005;25:1–160
  3. Margolis KL, Adami HO, Luo J, Ye W, Weiderpass E. A prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women. Fertil Steril. 2007;88:310–316
  4. Glasier AF, Smith KB, van der Spuy ZM, et al. Amenorrhea associated with contraception - an international study on acceptability. Contraception. 2003;67:1–8
  5. Sulak PJ, Buckley T, Kuehl TJ. Attitudes and prescribing preferences of health care professionals in the United States regarding use of extended-cycle oral contraceptives. Contraception. 2006;73:41–45
  6. Wiegratz I, Hommel HH, Zimmermann T, Kuhl H. Attitude of German women and gynecologists towards long-cycle treatment with oral contraceptives. Contraception. 2004;69:37–42
  7. Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med. 2003;349:1443–1450
  8. Speroff L, DeCherney A. Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins. Obstet Gynecol. 1993;81:1034–1047
  9. Taneepanichskul S, Phupong V. Influence of a new oral contraceptive with drospirenone on lipid metabolism. Gynecol Endocrinol. 2007;23:347–350
  10. Endrikat J, Klipping C, Cronin M, et al. An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 mcg ethinyl estradiol and 100 mcg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. Contraception. 2002;65:215–221
  11. Chasan-Taber L, Willett WC, Stampfer MJ, et al. A prospective study of oral contraceptives and NIDDM among U.S. women. Diabetes Care. 1997;20:330–335
  12. Kim C, Siscovick DS, Sidney S, Lewis CE, Kiefe CI, Koepsell TD. Oral contraceptive use and association with glucose, insulin, and diabetes in young adult women: the CARDIA study. Coronary Artery Risk Development in Young Adults. Diabetes Care. 2002;25:1027–1032
  13. Machado RB, Fabrini P, Cruz AM, Maia E, da Cunha Bastos A. Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 microg) and gestodene (75 microg). Contraception. 2004;70:365–370
  14. Wiegratz I, Stahlberg S, Manthey T, et al. Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters. Contraception. 2008;78:384–391
  15. Kwiecien M, Edelman A, Nichols MD, Jensen JT. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception. 2003;67:9–13
  16. Apter D, Borsos A, Baumgärtner W, et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care. 2003;8:37–51
  17. Klipping C, Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception. 2005;71:409–416

PII: S0010-7824(09)00388-6

doi: 10.1016/j.contraception.2009.08.009

Contraception
Volume 81, Issue 2 , Pages 102-106 , February 2010

Article Tools